Cantor halves Ardelyx PT to $7 from $14; maintains OW rating

Jul 30, 2021 · Cantor Fitzgerald slashed its price target for Ardelyx (NASDAQ:ARDX) to $7 from $14 after the company received a complete response letter from the FDA for its NDA for …

$7
OFF

Cantor Halves Ardelyx PT To $7 From $14; Maintains OW Rating

1 week from now

Jul 30, 2021 · Cantor Fitzgerald slashed its price target for Ardelyx (NASDAQ:ARDX) to $7 from $14 after the company received a complete response letter from the FDA for its NDA for …

biotuesdays.com

07%
OFF

Ardelyx, Inc. (ARDX) Analyst Ratings - Stock Analysis

1 week from now

4 days ago · A list of analyst ratings for Ardelyx (ARDX) stock. See upgrades, downgrades, price targets and more from top Wall Street stock analysts. ... Maintains: $14 → $10 +70.07%: Jul 3, …

stockanalysis.com

$10
OFF

Ardelyx, Inc.: Target Price Consensus And Analysts …

1 week from now

Jan 3, 2025 · Cantor Fitzgerald Upgrades Ardelyx to Overweight From Neutral, Adjusts Price Target to $10 From $5 23-08-25: MT Ladenburg Thalmann Adjusts Price Target on Ardelyx to …

marketscreener.com

$14
OFF

Ardelyx : Cantor Fitzgerald Starts Ardelyx At Overweight With $14 …

1 week from now

-- Ardelyx has an average rating of buy and price targets ranging from $11 to $15, according to analysts polled by Capital IQ. Price: 6.75, Change: +0.40, Percent Change: +6.30 ...

marketscreener.com

$7
OFF

Ardelyx : Citigroup Adjusts Price Target On Ardelyx To $7 From $16 ...

1 week from now

-- Ardelyx has an average rating of outperform and price targets ranging from $2 to $14, according to analysts polled by Capital IQ. Price: 2.0100, Change: -5.6900, Percent Change: ...

marketscreener.com

29%
OFF

Analyst Ratings Of ARDELYX INC(NASDAQ:ARDX) Stock

1 week from now

ARDELYX INC (ARDX) US0396971071 - Common Stock . 5.34 -0.07 (-1.29%) After market ... ChartMill assigns a Buy % Consensus number of 86% to ARDX. The Buy consensus is the …

chartmill.com

$10.50
OFF

Cantor Fitzgerald Upgrades Ardelyx (ARDX) - Nasdaq

1 week from now

As of August 2, 2023, the average one-year price target for Ardelyx is 7.22. The forecasts range from a low of 5.05 to a high of $10.50. The forecasts range from a low of 5.05 to a high of $10.50.

nasdaq.com

$7.80
OFF

Cantor Upgrades Ardelyx To Overweight Ahead Of FDA Decision On …

1 week from now

Aug 25, 2023 · Stock was at around $7.80 prior to CRL and was expected to jump to around $12 - $14 with approval. Since, Ardelyx has met the FDA requirements but more importantly, an …

seekingalpha.com

$3
OFF

Cantor Fitzgerald Adjusts Price Target On Ardelyx To $3 From

1 week from now

08:48AM EST, 12/29/2022 (MT Newswires) -- Ardelyx (ARDX) has an average outperform rating and a price target range of $2 to $8, according to analysts polled by Capital IQ. (MT …

moomoo.com

$3
OFF

Cantor Ups Ardelyx PT To $3 After FDA Update - BioTuesdays

1 week from now

Dec 29, 2022 · Cantor Fitzgerald raised its price target for Ardelyx (NASDAQ:ARDX) to $3 from $1.60 but maintained a “neutral” rating after a label update from the FDA. The stock closed at …

biotuesdays.com

$3
OFF

BioTuesdays On LinkedIn: Cantor Ups Ardelyx PT To $3 After FDA …

1 week from now

Cantor Fitzgerald raised its price target for Ardelyx, Inc. (NASDAQ:ARDX) to $3 from $1.60 but maintained a “neutral” rating after a label update from the…

linkedin.com

$10
OFF

BioTuesdays On LinkedIn: Cantor Ups Ardelyx To OW; PT To $10 …

1 week from now

Cantor Fitzgerald upgraded Ardelyx, Inc. (NASDAQ:ARDX) to “overweight” from “neutral” and doubled its price target to $10 from $5, citing an upcoming PDUFA…

linkedin.com

$14
OFF

Citigroup Raises Price Target On Ardelyx To $14 From $9, …

1 week from now

-- Ardelyx has an average buy rating and price target range of $9 to $15, according to analysts polled by Capital IQ. Price: 9.14, Change: +0.04, Percent Change: +0.44 ...

marketscreener.com

$3
OFF

Cantor Fitzgerald Adjusts Price Target On Ardelyx To $3 From $1.60 ...

1 week from now

-- Ardelyx has an average outperform rating and a price target range of $2 to $8, according to analysts polled by Capital IQ. Price: 2.58, Change: +0.07, Percent Change: +2.85 ...

marketscreener.com

120%
OFF

Cantor Initiates With Overweight Rating For Scynexis And Ardelyx On ...

1 week from now

PT set to $14, implies a 120% increase from last price. Ardelyx average PT is $13.67. Also, last month, SVB Leerink raised the PT of the company to $14 from $11 per share .

seekingalpha.com

$43
OFF

Cantor Starts Nyxoah At OW; PT $43 - BioTuesdays

1 week from now

Jul 28, 2021 · Cantor starts Nyxoah at OW; PT $43. July 28, 2021. Cantor Fitzgerald initiated coverage of Nyxoah SA (NASDAQ:NYXH) with an “overweight” rating and 12-month price …

biotuesdays.com

$7
OFF

BTIG Cuts Misonix To Neutral On Proposed Acquisition By Bioventus

1 week from now

Jul 30, 2021 · Cantor halves Ardelyx PT to $7 from $14; maintains OW rating. You may also like. Markets. ... PT $37. Stifel launched coverage of Disc Medicine (NASDAQ:IRON) with a “buy” …

biotuesdays.com

FAQs about Cantor halves Ardelyx PT to $7 from $14; maintains OW rating Coupon?

Why did Cantor Fitzgerald upgrade Ardelyx to overweight?

Cantor Fitzgerald has upgraded Ardelyx ( NASDAQ: ARDX) to overweight in anticipation that the FDA will soon approve its drug Xphozah for the control of serum phosphate levels in dialysis patients. ...

What is the average one-year price target for Ardelyx?

As of August 2, 2023, the average one-year for Ardelyx is 7.22. The forecasts range from a low of 5.05 to a high of $10.50. The average price target represents an increase of 105.84% from its latest reported closing price of 3.51. leaderboard of companies with the largest price target upside. ...

What is Ardelyx Tenapanor?

Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company's NDA is currently under review by the FDA, with a PDUFA date of April 29, 2021. ...

How much did Ardelyx stock go up before CRL?

Stock was at around $7.80 prior to CRL and was expected to jump to around $12 - $14 with approval. Since, Ardelyx has met the FDA requirements but more importantly, an independent panel assigned to review the drug approved the drug with their "stamp" at a 10-2 decision. That's overwhelming. ...

What does Ardelyx do?

Ardelyx is focused on discovering, developing, and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. ...

Why did Cantor upgrade xpohzah?

Cantor said its upgrade was based on the potential for Ardelyx’s drug Ibsrela to continue to beat expectations, a “greater appreciation” for the total addressable market for Xpohzah in hyperphosphatemia, and a possible delay of the inclusion of phosphate-lowering drugs into the Medicare dialysis bundle from 2025 to 2033. ...